MDM2 Inhibitor AMG-232, Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Hypercalcemia; Plasmacytoma; Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma Interventions: Drug: Carfilzomib; Drug: Dexamethasone; Other: Laboratory Biomarker Analysis; Drug: Lenalidomide; Drug: MDM2 Inhibitor AMG-232; Other: Pharmacological Study Sponsor: National Cancer Institute (NCI) Not yet recruiting - verified February 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials